TL;DR
This massive population-level study of 42 million people in England quantifies the risk of myocarditis across three doses of COVID-19 vaccines compared to SARS-CoV-2 infection. While the risk of myocarditis is generally higher following infection, younger males (<40) face a significantly higher risk specifically after a second dose of the mRNA-1273 (Moderna) vaccine.
What Problem Does This Paper Address?
Early in the global vaccination campaign, reports emerged linking mRNA vaccines to myocarditis (inflammation of the heart muscle). While initial studies confirmed this link, several questions remained:
- How does the risk change with a third (booster) dose?
- How does the risk vary when strictly stratified by age and sex?
- How does the vaccine-associated risk compare to the risk of myocarditis caused by the virus itself?
The authors aimed to provide a comprehensive, granular analysis to help policy makers and clinicians weigh the risks and benefits of sequential vaccination across different demographic groups.
Methods
The researchers employed a Self-Controlled Case Series (SCCS) design. This is a powerful epidemiological tool where individuals who experience the outcome (myocarditis) act as their own controls. By comparing the incidence of myocarditis during "risk periods" (1–28 days post-vaccination or post-infection) to "baseline periods" (time spent outside those windows), the model implicitly controls for fixed individual characteristics like genetics, chronic health conditions, and socioeconomic status.
They calculated Incidence Rate Ratios (IRRs) and estimated the number of excess events per million people exposed.
Datasets
The study utilized a massive, linked dataset from England:
- NIMS (National Immunisation Management Service): To identify vaccine type, date, and dose for all vaccinated individuals.
- HES (Hospital Episode Statistics) & ONS (Office for National Statistics): To track hospital admissions and deaths related to myocarditis.
- SGSS (Second Generation Surveillance System): To identify positive SARS-CoV-2 test results.
The final cohort included 42,200,614 people aged 13 and older, including nearly 11 million who had received a third dose.
Key Insights and Ideas
- The "Young Male" Vulnerability: The association between vaccination and myocarditis is most pronounced in males under 40. This demographic consistently showed higher IRRs across almost all vaccine types and doses compared to females or older males.
- Dose-Dependent Risk: For mRNA vaccines, the risk was generally higher after the second dose than the first. The study also provides the first clear evidence of a small but statistically significant increase in risk following a third dose of the BNT162b2 (Pfizer) vaccine.
- The Moderna Exception: While Pfizer and AstraZeneca (ChAdOx1) showed modest increases in risk, the mRNA-1273 (Moderna) vaccine stood out. In younger males, the second dose of Moderna carried a risk substantially higher than that of the infection itself.
- Infection is Still the Primary Driver for Most: For the general population and specifically for those over 40, the risk of myocarditis from a COVID-19 infection far outweighs the risk from any vaccine dose.
Key Results
- Overall Booster Risk: A third dose of Pfizer (BNT162b2) was associated with an IRR of 2.02 (95% CI 1.40, 2.91) for myocarditis in the overall population.
- Younger Males (<40) - The Critical Subgroup:
- 2nd Dose Moderna: An estimated 101 additional events per million (IRR 16.52).
- 2nd Dose Pfizer: An estimated 12 additional events per million (IRR 3.41).
- SARS-CoV-2 Infection: An estimated 7 additional events per million (IRR 2.02).
- Older Population: In males over 40, a positive SARS-CoV-2 test was associated with 73 additional myocarditis events per million, compared to only 3 additional events following a third Pfizer dose.
Limitations and Future Work
- Small Sample Sizes for Some Boosters: At the time of the study, the number of people receiving a third dose of Moderna or AstraZeneca was too small to reliably estimate their specific booster risks.
- Data Source Constraints: The study relied on hospital discharge codes and death certificates. This likely captures the most severe cases but may miss milder cases of myocarditis that did not require hospitalization.
- Pediatric Data: While the study included children aged 13–17, the absolute number of myocarditis events in this specific bracket was too small (n=15 in the risk period) to conduct a robust independent analysis. The authors call for international pooling of data to better understand risks in children.
- Booster Timing: As booster programs continue, future research will need to evaluate the impact of different intervals between doses and the effects of "mixing and matching" vaccine types.
Summary updated